Inovio Pharma tumbles on planned stock offering
** Inovio Pharmaceuticals INO.O shares down 20.5% at
$2.99 post-market as co plans equity raise
** Co, which focuses on treating
(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper@tr.com 1-646-279-6380))
Recent news on Inovio Pharmaceuticals
See all newsBrief: Inovio Announces Favorable Judgment In Litigation With Vgxi, Inc. And Geneone Life Science
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Inovio Q2 net loss narrows on warrant gain, lower costs
Brief: Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million